Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

Description

This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.

Conditions

Recurrent Renal Cell Carcinoma, Renal Cell Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.

Multi-Modality Detection of RCC Recurrence Post Ablation

Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

Condition
Recurrent Renal Cell Carcinoma
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States, 19107

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Previously received cryotherapy or microwave therapy of RCC
  • * Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy
  • * Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study
  • * Be at least 18 years of age
  • * Be medically stable
  • * If a female of child-bearing age, must have a negative pregnancy test
  • * Have signed Informed Consent to participate in the study
  • * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
  • * Patients with known sensitivities to the components of Lumason

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

john eisenbrey,

Study Record Dates

2028-02